JP2022501355A5 - - Google Patents
Info
- Publication number
- JP2022501355A5 JP2022501355A5 JP2021515150A JP2021515150A JP2022501355A5 JP 2022501355 A5 JP2022501355 A5 JP 2022501355A5 JP 2021515150 A JP2021515150 A JP 2021515150A JP 2021515150 A JP2021515150 A JP 2021515150A JP 2022501355 A5 JP2022501355 A5 JP 2022501355A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- erdafitinib
- fgfr
- dose
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862734501P | 2018-09-21 | 2018-09-21 | |
| US62/734,501 | 2018-09-21 | ||
| PCT/EP2019/075222 WO2020058432A1 (en) | 2018-09-21 | 2019-09-19 | Treatment of cholangiocarcinoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022501355A JP2022501355A (ja) | 2022-01-06 |
| JP2022501355A5 true JP2022501355A5 (cg-RX-API-DMAC7.html) | 2022-09-22 |
| JP7761485B2 JP7761485B2 (ja) | 2025-10-28 |
Family
ID=68289904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021515150A Active JP7761485B2 (ja) | 2018-09-21 | 2019-09-19 | 胆管癌の処置 |
Country Status (15)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021011926A (es) | 2019-03-29 | 2021-11-03 | Janssen Pharmaceutica Nv | Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial. |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| CA2744096C (en) | 1996-07-31 | 2013-07-30 | Laboratory Corporation Of America Holdings | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| DE19802377A1 (de) * | 1998-01-22 | 1999-08-19 | Max Planck Gesellschaft | Verwendung von Inhibitoren für die Behandlung von RTK-Überfunktions-bedingten Störungen, insbesondere von Krebs |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| EP2270000B1 (en) | 2005-05-23 | 2015-07-29 | Novartis AG | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| AR088941A1 (es) | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | Anticuerpos anti-fgfr2 y sus usos |
| SG11201702381QA (en) * | 2014-09-26 | 2017-04-27 | Janssen Pharmaceutica Nv | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor |
| CN114984013A (zh) * | 2015-03-25 | 2022-09-02 | 国立癌症研究中心 | 胆管癌治疗剂 |
| EP3365335B1 (en) * | 2015-10-23 | 2024-02-14 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases |
| MA47408B1 (fr) * | 2017-12-20 | 2023-08-31 | Janssen Pharmaceutica Nv | Traitement du cancer |
| CA3100422A1 (en) * | 2018-05-16 | 2019-11-21 | Debiopharm International, S.A. | Dosing regimens for treatment of solid tumors having one or more genetic alterations in fgfr1, fgfr2, and/or fgfr3 |
-
2019
- 2019-09-19 KR KR1020217011356A patent/KR20210064274A/ko not_active Withdrawn
- 2019-09-19 US US17/275,720 patent/US12133851B2/en active Active
- 2019-09-19 EA EA202190826A patent/EA202190826A1/ru unknown
- 2019-09-19 BR BR112021005271-2A patent/BR112021005271A2/pt unknown
- 2019-09-19 AU AU2019342289A patent/AU2019342289A1/en not_active Abandoned
- 2019-09-19 JO JOP/2021/0052A patent/JOP20210052A1/ar unknown
- 2019-09-19 EP EP19789863.8A patent/EP3852756A1/en active Pending
- 2019-09-19 JP JP2021515150A patent/JP7761485B2/ja active Active
- 2019-09-19 SG SG11202102546XA patent/SG11202102546XA/en unknown
- 2019-09-19 MA MA053655A patent/MA53655A/fr unknown
- 2019-09-19 WO PCT/EP2019/075222 patent/WO2020058432A1/en not_active Ceased
- 2019-09-19 MX MX2021003320A patent/MX2021003320A/es unknown
- 2019-09-19 CN CN201980061681.3A patent/CN112739347A/zh active Pending
-
2021
- 2021-03-17 IL IL281595A patent/IL281595A/en unknown
- 2021-03-18 PH PH12021550628A patent/PH12021550628A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chuk et al. | A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group | |
| Kim et al. | Bisphosphonates induce senescence in normal human oral keratinocytes | |
| Yamamoto et al. | A Phase I, dose‐finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors | |
| US20230130243A1 (en) | Method of Treating Urothelial Carcinoma and Other Genitourinary Malignancies Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | |
| van Doorn et al. | Effect of garlic powder on C-reactive protein and plasma lipids in overweight and smoking subjects | |
| JP2017503823A (ja) | プリドピジンの調節放出製剤 | |
| JP2020521794A5 (cg-RX-API-DMAC7.html) | ||
| Modi et al. | Effect of food on the pharmacokinetics of osmotic controlled‐release methylphenidate HCl in healthy subjects | |
| JP6410795B2 (ja) | カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物 | |
| KR20050044587A (ko) | B형 간염 바이러스 감염 치료용 포스포네이트뉴클레오타이드 유사체의 용도 | |
| RU2753523C2 (ru) | УЛУЧШЕННЫЙ ТЕРАПЕВТИЧЕСКИЙ ИНДЕКС ИНГИБИТОРОВ ПРОТИВ ИММУННОЙ КОНТРОЛЬНОЙ ТОЧКИ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ, ВКЛЮЧАЮЩЕЙ ЭКСТРАКТ PHY906, ЭКСТРАКТ Scutellaria baicalensis Georgi (S) ИЛИ СОЕДИНЕНИЕ ИЗ ТАКИХ ЭКСТРАКТОВ | |
| Mooss et al. | Efficacy and tolerance of high-dose intravenous amiodarone for recurrent, refractory ventricular tachycardia | |
| JP2022546550A5 (cg-RX-API-DMAC7.html) | ||
| Krens et al. | Exposure‐toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer | |
| KR20200058108A (ko) | IRE1α 또는 XBP1의 활성 억제제를 유효성분으로 포함하는 항암제 민감성 증진용 약학적 조성물 | |
| EA013813B1 (ru) | Применение иматиниба для лечения гепатита с | |
| Sakaguchi et al. | Effectiveness of additional immunosuppressive drugs for corticosteroid-refractory immune checkpoint inhibitor-induced myocarditis: two case reports | |
| Creasey et al. | Pharmacokinetics of captopril in elderly healthy male volunteers | |
| WO2016112381A1 (en) | Restoring physiology in iron-deficient organisms using small molecules | |
| WO2021175432A1 (en) | Method for administration of an anti cancer agent | |
| Gao et al. | Investigation of human pharmacoscintigraphic behavior of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug (efavirenz) | |
| JP2024507221A5 (cg-RX-API-DMAC7.html) | ||
| JP2024521696A5 (cg-RX-API-DMAC7.html) | ||
| Greenblatt et al. | Lidocaine plasma concentrations following administration of intraoral lidocaine solution | |
| JP2023538065A5 (cg-RX-API-DMAC7.html) |